Nabi Biopharmaceuticals Announces First Quarter 2007 Financial Results

BOCA RATON, Fla., May 2 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (NASDAQ: NABI) today announced its first quarter financial results. The company recorded a net loss from continuing operations of $10.7 million, or $0.17 per share, for the quarter ended March 31, 2007, compared to $15.5 million, or $0.26 per share for the quarter ended April 1, 2006. Revenues for the first quarter of 2007 were $23.7 million compared to $19.5 million in 2006, an increase of 22%. Nabi-HB(R) [Hepatitis B Immune Globulin (Human)] revenues were $10.1 million during the first quarter of 2007 compared to $7.2 million during the first quarter of 2006.

Total cash used in operating activities was $7.7 million during the first quarter of 2007, a 65% reduction compared to $22.1 million in the first quarter of 2006. Excluding discontinued operations, cash used in operating activities was $5.8 million compared to $11.7 million for quarters ended March 31, 2007 and April 1, 2006, respectively. Cash equivalents and marketable securities were $111.2 million at the end of the first quarter.

"During the first quarter of this year, we were able to continue our reduction of Nabi's cash burn while simultaneously driving higher revenues across our antibody and pharmaceutical products, including growth for Nabi-HB when compared to the first quarter of last year," said Dr. Leslie Hudson, interim president and chief executive officer of Nabi Biopharmaceuticals. "Additionally, we've just announced today the positive results of our Phase IIb NicVAX trial. We believe that the achievements of these robust financial and clinical milestones will help to unlock value for our shareholders."

  Recent Accomplishments

  * May 2007 - Announced positive results from its Phase IIb 'proof of
    concept' trial for NicVAX(R) (Nicotine Conjugate Vaccine) (Please see
    the Nabi press release, "Nabi Biopharmaceuticals Announces Positive
    Results of Phase IIb Trial of NicVAX" issued earlier today)
  * April 2007 - Entered into a definitive agreement to sell Aloprim(TM)
    (allopurinol sodium) for Injection to Bioniche Teoranta for sales
    proceeds of $3.7 million
  * April 2007 - Named Stephan E. Lawton senior vice president and general
    counsel
  * March 2007 - Announced our intent to form two strategic business
    units - Nabi Biologics and Nabi Pharmaceuticals - to best realize the
    company's value and drive the successful development of its diverse
    product pipeline
  * February 2007 - Named Dr. Leslie Hudson interim president and chief
    executive officer
  * February 2007 - Named Dr. Paul Kessler senior vice president, clinical,
    medical and regulatory affairs
  * January 2007 - Announced initiation of Phase II 'proof of concept'
    clinical trial for Civacir(R) [Hepatitis C Immune Globulin (Human)]

  Upcoming Milestones

  * Nabi is currently working toward achieving the following corporate
    milestones in 2007:
  * Successfully complete the strategic alternatives process
  * Obtain approval for Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin
    (Human) Intravenous] in the U.S.
  * Secure development partnerships for NicVAX and the Gram-positive
    programs
  * Complete enrollment in the 'proof of concept' clinical trial for Civacir
  * Resubmit the file for regulatory approval of HEBIG(TM) [Hepatitis B
    Immune Globulin (Human) Intravenous] in Europe
  * Accelerate patient recruitment in the Phase III trial of ATG-Fresenius S
    (anti-T-lymphocyte globulin) in lung transplant patients
  * Initiate the clinical trial of our intravenous immunoglobulin, IVIG

  Review of Operations:

Nabi-HB revenues were $10.1 million for the quarter ended March 31, 2007 compared to $7.2 million for the quarter ended April 1, 2006. End user demand for Nabi-HB increased slightly during the first quarter compared to the first quarter of 2006. During the first quarter of 2006, our wholesaler customers reduced their Nabi-HB inventory stocking levels, which resulted in lower purchases of the product.

Other biopharmaceutical revenues were $1.5 million during the first quarter of 2007 compared to $0.7 million during the 2006 first quarter. This increase was due to increased contract manufacturing activities.

Total antibody revenues were $12.1 million during the first quarter of 2007 compared to $11.7 million during the first quarter of 2006.

Research and development expenses increased $1.3 million to $10.1 million during the first quarter of 2007, compared to $8.8 million during the first quarter of 2006. This increase was due to increased activities related to our Anti-D, IVIG and ATG-Fresenius S programs, which were initiated during 2006, partially offset by decreased spending on StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine).

Selling, general and administrative expenses decreased $1.7 million to $10.0 million in the first quarter of 2007, compared to $11.7 million during the first quarter of 2006. This decrease is the result of lower personnel and marketing-related expenses incurred in the current year quarter as we continue to lower our overall infrastructure costs.

First Quarter Financial Results Conference Call

Nabi will host a live webcast today at 4:30 p.m. ET to discuss the results of its Phase IIb NicVAX trial as well as these first quarter 2007 results.

The live webcast can be accessed at http://phx.corporate-/ ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1523652 or via the Nabi Biopharmaceuticals Web site: http://www.nabi.com/. If you do not have Internet access, the U.S./Canada call-in number is (800) 901-5259, conference code 52348815, and the international call-in number is (617) 786-4514, conference code 52348815. An audio replay will be available for U.S./Canada callers at (888) 286-8010, conference code 36684499, and for international callers at (617) 801-6888, conference code 36684499.

An archived version of the webcast will be available at the same Internet address through May 9, 2007. The audio replay also will be available through May 9, 2007. The press release will be available on the company's Web site: http://www.nabi.com/.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has two products on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection which Nabi recently agreed to sell to Bioniche Teoranta - that transaction is expected to close in the second quarter of 2007. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. The company recently announced that it intends to form two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics will have responsibility for the company's protein and immunological products and development pipeline, including Nabi-HB. Nabi Pharmaceuticals will have responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs, as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate). For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com/.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward- looking statements and include statements about our agreement to sell Aloprim and the expected proceeds from the sale, reorganization of our current business into two new business units, clinical trials and studies, licensure applications, and alliances and partnerships. You can identify these forward- looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: successfully partner with third parties to fund, develop, manufacture and/or distribute our existing and pipeline products, including NicVAX and our Gram-positive infections products; obtain successful clinical trial results; generate sufficient cash flow from sales of products or from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to commercialize current products and bring to market products in development; depend upon third parties to manufacture or fill our products; obtain regulatory approval for our products in the U.S. or other markets, including approval of Nabi-HB Intravenous; realize sales from Nabi-HB due to patient treatment protocols, the number of liver transplants performed in HBV- positive patients and competitive products; achieve market acceptance of our products; expand our sales and marketing capabilities or enter into and maintain arrangements with third parties to market and sell our products; effectively and/or profitability use, or utilize the full capacity of, our vaccine manufacturing facility; manufacture NicVAX or other products in our own vaccine manufacturing facility; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 30, 2006 filed with the Securities and Exchange Commission on March 15, 2007.

                         Nabi Biopharmaceuticals

             CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                               (Unaudited)

                 (In thousands, except per share amounts)

                                                  For the Three Months Ended
                                                       March 31,    April 1,
                                                          2007        2006

  Revenues                                              $23,748    $19,517
  Costs and expenses:
    Costs of products sold, excluding amortization
     of intangible assets                                14,316     14,092
    Royalty expense                                         423        356

  Gross margin, excluding amortization of
   intangible assets                                      9,009      5,069
    Selling, general and administrative expense           9,968     11,677
    Research and development expense                     10,056      8,778
    Amortization of intangible assets                        68         68
    Other operating expenses, principally freight            45        179

  Operating loss                                        (11,128)   (15,633)
  Interest income                                         1,580      1,063
  Interest expense                                         (917)      (953)
  Other (expense) income, net                                (2)        65

  Loss from continuing operations before income taxes   (10,467)   (15,458)
  Income taxes                                             (190)         -

  Loss from continuing operations                       (10,657)   (15,458)

  Net loss from discontinued operations                    (372)    (2,619)

  Net loss                                             $(11,029)  $(18,077)
  Basic and diluted loss per share
    Continuing operations                                $(0.17)   $ (0.26)
    Discontinued operations                               (0.01)     (0.04)

  Basic and diluted loss per share                       $(0.18)   $ (0.30)

  Basic and diluted weighted average shares
   outstanding                                           61,258     60,329



  Supplemental Information:

  (In thousands, except percentages)

                                           For the Three Months Ended
  Biopharmaceutical Products:         March 31, 2007        April 1, 2006
    - Nabi-HB                       $10,091       43%      $7,161      36%
    - Other Biopharmaceuticals        1,511         6         704        4
        Biopharmaceutical subtotal   11,602        49       7,865       40
  Antibody Products:
    - Specialty antibodies            5,130        21       5,878       30
    - Non-specific antibodies         7,016        30       5,774       30
        Antibody subtotal            12,146        51      11,652       60
  Total                             $23,748      100%     $19,517     100%



                         Nabi Biopharmaceuticals

                  CONDENSED CONSOLIDATED BALANCE SHEETS

                               (Unaudited)

                              (In thousands)


                                                      March 31, December 30,
                                                         2007        2006
  Assets
  Current assets:
    Cash                                                $84,663    $86,227
    Marketable securities                                26,500     32,500
    Restricted cash                                         805        805
    Trade accounts receivable, net                       17,200     20,377
    Inventories, net                                     17,770     19,260
    Prepaid expenses and other current assets             3,044      2,654
    Assets of discontinued operations                       309     13,341

      Total current assets                              150,291    175,164

  Property, plant and equipment, net                     86,566     88,329
  Other assets:
    Intangible assets, net                                1,615      1,683
    Other, net                                              676        701

  Total assets                                         $239,148   $265,877

  Liabilities and stockholders' equity
  Current liabilities:
    Trade accounts payable                               $7,450     $7,998
    Accrued expenses                                     14,305     16,095
    Capital lease obligations, net                          229        291
    Liabilities of discontinued operations                6,013     20,554

      Total current liabilities                          27,997     44,938
  2.875% convertible senior notes, net                  109,355    109,313
  Other liabilities                                         829        238

      Total liabilities                                 138,181    154,489

  Commitments and contingencies
  Stockholders' equity:
    Convertible preferred stock                               -          -
    Common stock                                          6,145      6,149
    Capital in excess of par                            327,838    327,228
    Treasury stock                                       (5,321)    (5,321)
    Accumulated deficit                                (227,695)  (216,668)

      Total stockholders' equity                        100,967    111,388

  Total liabilities and stockholders' equity           $239,148   $265,877



                         Nabi Biopharmaceuticals

             CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                               (Unaudited)

                              (In thousands)

                                                  For the Three Months Ended
                                                      March 31,    April 1,
                                                         2007       2006

  Cash flow from operating activities:
    Net loss from continuing operations                $(10,657)  $(15,458)
    Adjustments to reconcile net loss to net cash
     used in operating activities:
      Depreciation and amortization                       2,156      2,237
      Accretion of discount on convertible senior notes      42         42
      Interest expense on non-interest bearing notes          -         10
      Provision for doubtful accounts                         4         21
      Provision for slow moving or obsolete inventory        81        305
      Non-cash compensation                                 490        445
      Disposal of fixed assets, net                          13         47
      Other, primarily foreign currency translation           -       (182)
    Changes in assets and liabilities:
      Trade accounts receivable                           3,173      4,862
      Inventories                                         1,409       (821)
      Prepaid expenses and other current assets            (390)       503
      Other assets                                           21         58
      Accounts payable and accrued expenses              (2,106)    (3,731)

    Total adjustments                                     4,893      3,796
    Net cash used in operating activities from
     continuing operations                               (5,764)   (11,662)
    Net cash used in operating activities from
     discontinued operations                             (1,964)   (10,473)

  Net cash used in operating activities                  (7,728)   (22,135)
  Cash flow from investing activities:
      Purchases of marketable securities                 (9,750)   (50,600)
      Proceeds from sales of marketable securities       15,750     25,550
      Proceeds from sale of assets, net of
       closing costs                                          -          8
      Capital expenditures                                 (333)      (423)

    Net cash provided by (used in) investing
     activities from continuing operations                5,667    (25,465)
    Net cash provided by investing activities
     from discontinued operations                            82          -
  Net cash provided by (used in) investing activities     5,749    (25,465)
  Cash flow from financing activities:
      Repayments of notes payable and capital leases        (63)       (32)
      Proceeds from exercise of employee stock options      195        325
  Net cash provided by financing activities from
   continuing operations                                    132        293
  Net cash provided by (used in) financing activities
   from discontinued operations                             283     (3,059)
  Net cash provided by (used in) financing activities       415     (2,766)
  Net decrease in cash and cash equivalents              (1,564)   (50,366)
  Cash and cash equivalents at beginning of period       86,227    101,762
  Cash and cash equivalents at end of period            $84,663    $51,396